A Study of JNJ-79635322 in People With Multiple Myeloma

Full Title

A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Maximilian Merz’s office at 646-608-3713.

Protocol
26-359
Phase
Phase III (phase 3)
Investigator
Maximilian Merz
Co-Investigators
Saad Z. Usmani
Diseases
Hematology › Multiple Myeloma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07518186
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description